Clinical Performance of Plasma Metagenomic Sequencing in Immunocompromised Pediatric Patients

Alice C Lehman; Lea R Goren; Michael D Evans; Olivia Toles; Daniel Drozdov; Shannon L Andrews; Shane C McAllister; Beth K Thielen

doi:10.1093/jpids/piae024

Clinical Performance of Plasma Metagenomic Sequencing in Immunocompromised Pediatric Patients

J Pediatric Infect Dis Soc. 2024 May 30;13(5):276-281. doi: 10.1093/jpids/piae024.

Authors

Alice C Lehman^{1

2}, Lea R Goren³, Michael D Evans⁴, Olivia Toles¹, Daniel Drozdov^{5

6

7}, Shannon L Andrews¹, Shane C McAllister¹, Beth K Thielen¹

Affiliations

¹ Division of Pediatric Infectious Diseases, University of Minnesota, Minneapolis, USA.
² Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, USA.
³ University of Minnesota Medical School, Minneapolis, USA.
⁴ Clinical and Translational Science Institute, University of Minnesota, Minneapolis, USA.
⁵ Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, USA.
⁶ Division of Stem Cell Transplantation and Children's Research Center, University Children's Hospital Zurich, University of Zürich, Zürich, Switzerland, and.
⁷ Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kantonsspital Aarau, Aarau, Switzerland.

Abstract

The performance of plasma metagenomic next-generation sequencing was evaluated in an immunocompromised pediatric population. The clinical impact was limited, with management changes in 13% of cases. Moreover, organisms thought to be non-pathogenic were commonly detected. Prospective studies in specific populations are required to clarify the utility of this emerging technology.

Keywords: diagnostics; immunocompromised; metagenomic next-generation sequencing; pediatrics.

Publication types

Letter

MeSH terms

Adolescent
Child
Child, Preschool
Female
Humans
Immunocompromised Host*
Infant
Male
Metagenome
Metagenomics*
Plasma

Abstract

Publication types

MeSH terms

Grants and funding